Medically reviewed on August 12, 2018
(trye am SIN oh lone)
- Triamcinolone Acetonide
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Aerosol Solution, External, as acetonide:
Kenalog: 0.147 mg/g (63 g, 100 g)
Generic: 0.147 mg/g (63 g, 100 g)
Cream, External, as acetonide:
Triderm: 0.1% (28.4 g, 85.2 g); 0.5% (454 g) [contains propylene glycol]
Generic: 0.025% (15 g, 80 g, 453.6 g [DSC], 454 g); 0.1% (15 g, 30 g, 80 g, 453.6 g, 454 g); 0.5% (15 g)
Kit, External, as acetonide:
Dermasorb TA: 0.1% [contains cetyl alcohol, milk protein, propylene glycol]
Pediaderm TA: 0.1% [DSC] [contains cetyl alcohol, methylparaben, polysorbate 80, propylene glycol, propylparaben]
Lotion, External, as acetonide:
Generic: 0.025% (60 mL); 0.1% (60 mL)
Ointment, External, as acetonide:
Trianex: 0.05% (17 g [DSC], 85 g [DSC], 430 g)
Generic: 0.025% (15 g, 80 g, 454 g); 0.1% (15 g, 30 g, 80 g, 453.6 g, 454 g); 0.5% (15 g)
Paste, Mouth/Throat, as acetonide:
Oralone: 0.1% (5 g)
Generic: 0.1% (5 g)
Therapy Pack, External, as acetonide:
Dermazone: 0.1% (1 ea) [contains propylene glycol]
Brand Names: U.S.
- Dermasorb TA
- Pediaderm TA [DSC]
- Corticosteroid, Topical
Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Triamcinolone has intermediate to high range potency (dosage-form dependent).
Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, and the use of occlusive dressings.
Urine (40%); feces (60%, some via biliary excretion)
Biologic: 18 to 36 hours
Use: Labeled Indications
Dermatoses (corticosteroid-responsive): Topical: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Oral inflammatory and ulcerative lesions: Oral paste: Adjunctive treatment and temporary relief of symptoms associated with oral inflammatory and ulcerative lesions resulting from trauma
Hypersensitivity to triamcinolone or any component of the formulation; fungal, viral, or bacterial infections of the mouth or throat (oral topical formulation)
Oral topical formulations only: Fungal, viral, or bacterial infections of the mouth or throat
Dermatoses (corticosteroid-responsive): Topical: Note: Frequency of application based upon severity of condition
Cream, ointment: Apply thin film to affected areas 2 to 4 times daily
0.025%: Apply a thin film to affected area 3 to 4 times daily
0.1%: Apply a thin film to affected area 2 to 4 times daily
Aerosol solution: Apply to affected area 3 to 4 times daily
Oral inflammatory and ulcerative lesions: Oral paste: Press a small amount (about 1/4 inch) to the lesion at bedtime; a larger quantity may be required for coverage of some lesions. For severe lesions, may be used 2 or 3 times daily after meals.
Refer to adult dosing. Use the lowest effective dose.
Dermatoses (corticosteroid-responsive): Children and Adolescents: Topical: Note: Frequency based upon severity of condition: Cream, ointment, lotion, aerosol solution: Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling.
Aerosol solution: For external use only. Avoid heat, flame or smoking when using. Avoid eyes and do not inhale if spraying near face. Container may be used upright or inverted. When using the spray button, spray at a distance of three to six inches from affected area. For hard to reach areas, insert the spray tube applicator into spray button and twist to seat. Point tube away from body and face. Be sure the tube applicator is clean prior to use and wash after use. Move spray tube while applying, touching the surface of the affected area. Do not use tight fitting diapers or plastic pants on a patient being treated in the diaper area, as this constitutes an occlusive dressing. Occlusive dressing may be used if instructed by a health care professional; monitor for infection.
Cream, ointment: For external use only; avoid contact with eyes. Apply a thin film sparingly. May be used with occlusive dressings for management of psoriasis or recalcitrant conditions. If an infection develops, discontinue use of occlusive dressings.
Lotion: For external use only. Apply topical sparingly to affected areas as a thin film. May be used with occlusive dressings for management of psoriasis or recalcitrant conditions. If an infection develops, discontinue use of occlusive dressings. Not for ophthalmic use.
Oral paste: Do not apply paste to skin or eyes. Apply small amount into oral cavity until thin, smooth film develops; do not rub in; spreading the paste may result in a granular, gritty sensation and crumbling; apply at bedtime to allow contact of the medication with the lesion overnight; if more frequent application necessary, apply after meals.
Cream, ointment: Store at 20°C to 25°C (68°F to 77°F).
Lotion, oral paste: Store at 20°C to 25°C (68°F to 77°F). Do not freeze.
Aerosol solution: Store at room temperature; avoid excessive heat. Do not puncture or incinerate.
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination
Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. Monitor therapy
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Monitor therapy
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy
Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Monitor therapy
Frequency not defined.
Central nervous system: Localized burning
Dermatologic: Acneiform eruption, allergic contact dermatitis, atrophic striae, folliculitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, pruritus, secondary skin infection, skin atrophy, xeroderma
Endocrine & metabolic: HPA-axis suppression, hyperglycemia, hypokalemia
Local: Local irritation
Concerns related to adverse effects:
• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.
• Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.
• Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.
• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information
• Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.
• Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.
Dosage form specific issues:
• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.
• Administration: Aerosol solution: Do not apply to underarms or groin unless directed by a health care professional; if improvement is not seen within 2 weeks, contact prescriber. Product is flammable; avoid heat, smoking or flames when applying.
• Appropriate use: For external use only; avoid contact with eyes. Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; discontinue if skin irritation or contact dermatitis should occur; do not use in patients with decreased skin circulation.
• High-potency products: Avoid the use of high-potency steroids on the face.
• Oral cavity application: Do not apply paste to skin or eyes. When used as a topical agent in the oral cavity, if significant regeneration or repair of oral tissues has not occurred in seven days, re-evaluation of the etiology of the oral lesion is advised.
HPA axis suppression and adrenal insufficiency, especially in children. When used in the oral cavity (topical paste), if significant regeneration or repair of oral tissues has not occurred in seven days, re-evaluation of the etiology of the oral lesion is advised. When using aerosol solution, if no improvement is seen within 2 weeks, re-evaluation is advised.
Pregnancy Risk Factor
Adverse events have been observed in some animal reproduction studies. Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low birth weight infants following maternal use of potent or very potent topical products, especially in high doses. Use of mild to moderate potency topical corticosteroids is preferred in pregnant females and the use of large amounts or use for prolonged periods of time should be avoided (Chi 2016; Chi 2017; Murase 2014). Also avoid areas of high percutaneous absorption (Chi 2017). The risk of stretch marks may be increased with use of topical corticosteroids (Murase 2014).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience burning, itching, or dry skin. Have patient report immediately to prescriber signs of high blood sugar (confusion, fatigue, increased thirst, increased hunger, polyuria, flushing, fast breathing, or breath that smells like fruit), signs of skin changes (pimples, stretch marks, slow healing, or hair growth), signs of adrenal gland problems (severe nausea, vomiting, severe dizziness, passing out, muscle weakness, severe fatigue, mood changes, lack of appetite, or weight loss), signs of Cushings disease (weight gain in upper back or abdomen; moon face; severe headache; or slow healing), severe mouth irritation, skin irritation, skin discoloration, or skin thinning (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about triamcinolone topical
- Triamcinolone topical Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- 45 Reviews
- Drug class: topical steroids
- Triamcinolone Acetonide topical (AHFS Monograph)
- Triamcinolone (FDA)
- Triamcinolone Lotion (FDA)
- Triamcinolone Ointment (FDA)
- Triamcinolone Paste (FDA)
- Triamcinolone Topical Aerosol (FDA)